Helix Acquisition Corp. III

HLXC

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions.

Shell CompaniesCEO: Bihua ChenIPO: 2025Website ↗

Helix Acquisition Corp. III is a blank-check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses.

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.5/10

5 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 5 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

5 fund convergence

Perceptive Advisors

Cormorant Asset ManagementNew

RA Capital ManagementNew

EcoR1 CapitalNew

Commodore CapitalNew

Position history (shares)

Perceptive Advisors

Cormorant Asset Management

Commodore Capital

AI Signal

Perceptive Advisors fully exited HLXC, a SPAC vehicle, removing a previously held position entirely. Despite Perceptive's exit, 5 specialist biotech funds — including RA Capital, Cormorant, EcoR1, and Commodore — retain exposure, suggesting residual conviction in the underlying deal or target thesis.

Unlock full AI analysis — 14-day free trial

5 quarters